Document:

Filed by Bowne Pure Compliance

Exhibit 10.1

Confidential treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as [ * ].
A complete version of this exhibit has been filed separately with the Securities and Exchange
Commission.

LONG TERM PURCHASE AGREEMENT

This Agreement dated December 18, 2008, effective as of the date of the last signature to this
Agreement (the “Effective Date”)

BETWEEN

TomoTherapy Incorporated having its principal place of business at 1240 Deming Way, Madison, WI
53717, USA (hereinafter referred to as TOMO),

AND

E2V INC whose main place of business is at 4 Westchester Plaza, Elmsford, NY 10523, USA
(hereinafter referred to as E2V INC)

AND

E2V TECHNOLOGIES (UK) LIMITED having its principal place of business at 106 Waterhouse Lane,
Chelmsford, CM1 2QU, UK (hereinafter referred to as E2V LTD).

Each of the above may also be singularly referred to as the “Party” and collectively as the
“Parties”.

WHEREAS

E2V LTD manufactures inter alia modulators, modulator accessories and magnetron accessories (the
Products) and supplies these through E2V INC.

TOMO is an organisation that seeks to purchase from E2V INC quantities of the Products for
incorporation into and/or use with a medical device.

NOW IT IS HEREBY AGREED AS FOLLOWS

	1.	 	DEFINITIONS

In this Agreement (unless the context otherwise requires) the following expressions shall have the
following meanings:

	1.1	 	“Agreement” means these terms and conditions, all appendices and other documentation
referenced hereunder.

	 
	1.2	 	“Contract Price” means the price in the specified currency payable to E2V INC for Products to
be supplied under the Agreement free of taxes and bank and other charges of whatsoever nature.

	 
	1.3	 	“Intellectual Property Right” means any right derived from intellectual property such as
patents, petty patents, patent applications, registered and unregistered design rights,
copyright, trade secret and like protection.

 

 

 

	1.4	 	“Product” means the modulator, modulator accessory, and magnetron accessory devices
manufactured to the Specification, as specifically identified in Section 3.1 herein. Each
individual E2V INC part number listed in Section 3.1 may be referred to as a “Product Item”.

	 
	1.5	 	“Specification” means the most recently released version of the technical specification
relating to the Product.

	 
	1.6	 	“System” means the equipment into which the Product is to be installed.

	2.	 	DURATION

This Agreement will commence on the Effective Date and will continue for a period of [ * ] months
(the ‘Initial Term’). The Agreement may be renewed by written agreement between the Parties for a
subsequent period (the ‘Subsequent Terms’).

	3.	 	SCOPE OF SUPPLY FROM E2V

	 
	3.1	 	Subject to the following price and delivery terms, E2V INC shall supply the Products to TOMO
in accordance with this Agreement at the prices and with the warranty periods specified in
this Section 3.1.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	Total Contract	 	 	 	 
	 	 	 	Part	 	[ * ]-YR Unit	 	 	Order	 	 	 	 
	e2v P/N	 	 	Description	 	Price (GBP)	 	 	Quantity	 	 	Warranty	 
	[ * ]	 	 	Transition Piece
	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 
	[ * ]	 	 	Electromagnet
	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 
	[ * ]	 	 	SSM
	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 
	[ * ]	 	 	SSM Controller
	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 
	[ * ]	 	 	HV Power Supply
	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 
	[ * ]	 	 	HV Cable Assy
	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 
	[ * ]	 	 	Cable Assy
	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 
	[ * ]	 	 	Cable Assy
	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 
	[ * ]	 	 	Cable Assy
	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 
	[ * ]	 	 	Cable Assy
	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 

 

 

 

	3.2	 	TOMO will submit release purchase orders (RPO’s) to E2V INC on a 6 month rolling basis before
delivery is required by TOMO, E2V INC will confirm the acceptability of the delivery schedule
within 1 month of receipt of the RPO or advise an amendment to the delivery schedule. These
dates will be the due dates against which E2V INC will deliver Products. Deliveries scheduled
within the upcoming four (4) weeks will be fixed and not subject to change by either Party
other than by agreement.

	 
	3.3	 	TOMO commits to purchasing the Total Contract Order Quantity at Section 3.1 during the
Initial Term of this Agreement subject to the provisions of Sections 3.4 and 3.5, unless
otherwise agreed upon by the Parties. Additionally, to the extent required to fulfil the
Total Contract Order Quantities of this Agreement, TOMO commits to purchase all of its
manufacturing production requirements of the
Product from E2V INC as a sole source for the Product for the term of this Agreement.

	 
	3.4	 	The Parties will, on an annual basis, review the quantities purchased and forecast. In the
event that a lesser quantity than would reasonably be envisaged as being supplied within that
period in line with the Total Contract Order Quantity in section 3.1 is apparent then
conditional upon E2V remaining the sole source of supply in accordance with 3.3. E2V will work
with and support TOMO and will not invoke any failure to meet quantity default mechanism or
lower quantity break pricing bill back for the period.

	 
	3.5	 	However, the Parties will, during the third year of the Agreement, review the quantities
purchased to date and subject to a [ * ] ([ * ]%) percent tolerance margin will determine
whether the Total Contract Order Quantity for each Product Item identified in Section 3.1 will
be achieved based on best available twelve month TOMO forecasts. If the Parties agree that a
lesser quantity of any Product Item than the above-stated quantities will be purchased during
the Initial Term then E2V INC and E2V LTD reserve the right to adjust pricing against
anticipated quantity for that Product Item in line with the pricing breaks contained at
Exhibit A to reflect the sums due for the lower quantity purchased throughout the Initial
Term. Should E2V INC and E2V LTD adjust pricing against anticipated quantity as specified
herein, and should TOMO meet the original product estimates within the Initial Term plus six
months, E2V INC and/or E2V LTD shall credit any amounts paid by TOMO in increased prices
during the Initial Term to TOMO’s account.

	 
	3.6	 	In the event quantities are exceeded, E2V INC will make an effort to achieve better pricing
and extend to TOMO any applicable volume discounts or cost savings due to the increased
quantities.

 

 

 

	3.7	 	In the event that E2V is not the sole source of supply in accordance with the commitment at
Section 3.3 herein, then failure by TOMO to meet the Total Contract Order Quantity during the
Initial Term, subject to the tolerance margin of Section 3.5, or if E2V reasonably anticipates
this failure will occur at any point during the term based on RPO’s and TOMO forecast
information and after consultation with TOMO, shall entitle E2V INC to terminate the Agreement
for TOMO default in addition to invoicing for the sums due in accordance with the quantity
price breaks for the lower quantity purchased.

	 
	3.8	 	Quantities, prices and delivery for Subsequent Terms will be subject to formal amendment by
E2V INC following discussion with TOMO.

	 
	3.9	 	The terms and conditions of this Agreement shall prevail over and apply in precedence of any
other document, term or condition.

	4.	 	PRICE AND PAYMENT

	 
	4.1	 	The Contract Price shall be established in US$ one business day after the Effective Date for
the Agreement, based on the GBP pricing specified in Section 3.1, and be valid for twelve
months at the current twelve month forward rate as defined below.

	 
	4.2	 	E2V will obtain a quotation from its bank, as specified below, to determine the USD pricing
for the first 12-month period. At the end of that 12-month period, a further quote will be
obtained for the next 12-month period and then again at the end of that 12-month period for
the final 12-month period.

	 
	 	 	The exchange rate used to determine the USD pricing for each 12-month period will be the
average of the forward rates for each month for the 12 months going forward as quoted by
E2V’s bank. E2V will submit this quotation to TOMO for review and acceptance when
received. TOMO will be obliged to notify acceptance or rejection immediately. In the
event of rejection E2V will obtain two additional quotes on the same basis from two of its
other banks and will submit these to TOMO. TOMO will then immediately notify E2V which of
the rates should be implemented for the purposes of establishing the Contract Price. E2V
INC agrees that all quotations will be obtained from major international financial
institutions or banks.

	 
	4.3	 	The Price shall be the price on the Purchase Order and as stated above during the Initial
Term subject to any amendments in accordance with Section 3 and herein.

	 
	4.4	 	Prices for Subsequent Terms will be advised by E2V INC.

	 
	4.5	 	Unless otherwise agreed E2V INC shall invoice TOMO for Products on the date of their
despatch.

	 
	4.6	 	Payment will be 45 days open account against invoice with a credit line of $2.5 Million. The
credit line will be evaluated by the Parties as needs dictate.

	 
	4.7	 	If TOMO defaults under the terms of this Agreement with E2V INC in payment on the due date of
any sum due to E2V INC, E2V INC may without liability postpone delivery, without prejudice to
any other right or remedy which E2V INC may have against TOMO in respect of such default until
such time that the payment is made. Should E2V INC exercise its rights under this provision,
E2V INC agrees to immediately proceed with any postponed delivery upon receipt of payment by
TOMO.

 

 

 

	4.8	 	Title in the Product will transfer from E2V INC to TOMO upon receipt by E2V INC of payment in
full for each Product.

	 
	5.	 	DELIVERY

	 
	5.1	 	Products shall be delivered FCA, Madison, WI. (INCOTERMS 2000).

	 
	5.2	 	Subject to the provisions of Section 6, in the event of a delay at the fault of E2V INC in
the delivery of any Product, E2V INC shall after expiration of a 45 (forty five) day period of
grace be liable to pay TOMO in settlement for the delay, liquidated damages calculated at the
rate of [ * ]% ([ * ] per cent) on that part of the Contract Price relating to those Products
in delay for each complete week of the delay to a maximum of [ * ]% ([ * ] per cent) of that
part of the Contract Price relating to those Products in delay. E2V INC shall make reasonable
efforts to
avoid delays, including the use of overtime and capital expenditures to improve capacity
bottlenecks. In the event of recurring defaults by E2V INC on agreed delivery due dates,
and the Parties, having used all reasonable efforts and discussed in good faith, fail to
agree a plan to rectify this for future deliveries, then such recurring defaults may
constitute default of the Agreement by E2V INC.

	 
	5.3	 	Risk in the Products shall transfer from E2V INC to TOMO in accordance with the delivery term
specified.

	 
	5.4	 	TOMO shall inspect the Products upon delivery and may reject Products that do not conform to
the Specification provided that written notification of such rejection is submitted to E2V
INC. Products not notified as rejected within 30 days from delivery shall be deemed to be
accepted.

	 
	5.5	 	Products will be tested before delivery for conformance to Specification.

	 
	5.6	 	E2V INC shall not be responsible for the commissioning or installation of the Product into
any System.

	 
	5.7	 	TOMO reserves a right at all times to conduct quality and regulatory system audits of E2V INC
and E2V LTD for the purposes of assurance that the Products and the manufacturing processes
used to make them meet the quality and regulatory standards necessary for the Products to be
incorporated into or used with the System. Such audits, if necessary, will be performed at
mutually agreed-upon times. E2V INC and E2V LTD agree to have any necessary personnel present
for any such audits and agree to cooperate with TOMO in conducting any necessary audits. In
the event that issues arise as a result of these audits then the Parties will work together to
resolve these issues and will not use issues arising from the audit as grounds for finding E2V
INC in default of the Agreement unless such issues cannot be resolved by the Parties and cause
the Product to fail to meet the Specification. In the event that any issues arise from the
audit that cannot be resolved and such issues make it such that continued use of the Product
by TOMO in the System would cause TOMO to fail to meet its regulatory and quality obligations
with respect to the System, then TOMO shall have the right to terminate the Agreement, either
in whole or in part (with respect to one or more particular Product Items), subject to paying
the costs for termination specified in Section 11.3 herein.

 

 

 

	6.	 	FORCE MAJEURE

	 
	6.1	 	Neither Party shall be liable for any delay or failure to perform its obligations hereunder
which may be due to circumstances beyond its reasonable control and shall be entitled to such
extension of time thereof as may be reasonable in the circumstances. Such circumstances shall
include but not be limited to fire, flood, long term strikes, act of God and industrial action
at its plant or that or its subcontractor or supplier.

	 
	6.2	 	The Party experiencing the Force Majeure circumstance shall notify the other Party in writing
as soon as possible on becoming aware of such events described
in Section 6.1 and consult with the other Party concerning the subsequent treatment
thereof.

	 
	7.	 	WARRANTY

	 
	7.1	 	E2V INC shall warrant Products against defects in materials and workmanship, and failure to
meet the Specification for the periods stated above at clause 3, in accordance with E2V INC’s
standard conditions of warranty leaflet attached hereto as Exhibit B. Warranty will commence
when the Products are checked out of inventory by TOMO subject to a maximum warranty period of
[ * ] months from the date of delivery of the Products to TOMO.

	 
	7.2	 	The Parties hereby acknowledge and agree that the performance and application of the System
shall be the sole responsibility of TOMO.

	 
	8.	 	MODIFICATION TO SPECIFICATION

	 
	8.1	 	E2V INC reserve the right to make minor modifications to the Products specifications, designs
or materials that do not affect form, fit and function as E2V INC deem necessary. In the
event that any modifications are made to the Products, E2V INC shall notify TOMO prior to
delivery of Products incorporating the change so that TOMO may determine whether the changes
may affect the quality of the finished device.

	 
	8.2	 	Any change to a Product that reaches the threshold within the E2V INC quality system that it
would require the Product to receive either a major or minor revision increment shall be
approved in writing by TOMO before implementation, E2V shall provide thirty (30) days prior
written notice of such changes in order to enable TOMO to provide approval or rejection, or to
ask for reasonable additional time to complete any necessary testing and analysis with respect
to the continued use of the revised Product. TOMO will not unreasonably withhold approval.
TOMO’s failure to provide approval or rejection or to ask for reasonable additional time for
analysis of the impact of the proposed change within this period will be deemed an acceptance
of such changes.

 

 

 

	8.3	 	In the event that any Product is replaced with a new product or major revision, such as a
revision classified as a new product platform or one classified as a next generation product,
the Parties agree to review the quantities of the Products listed herein Section 3.1 to
determine what impact the major revision to that Product may have on TOMO’s forecasted product
need. The Parties agree to work together in good faith to reconcile this Agreement as
necessary with such new product or revision. Further, E2V INC agrees to work with TOMO in the
pursuit of technological improvements and cost down opportunities with respect to the Products
as requested by TOMO. TOMO will be given reasonable prior written notice of one hundred
eighty (180) days or such other time period as agreed upon by the Parties, of new products or
major Product revisions before implementation.

	 
	8.4	 	TOMO reserves the right to reject any changes to the Products proposed by E2V INC in the
event that such changes would not be backwards compatible with TOMO’s system or if such
changes would necessitate TOMO undertaking
additional work in its installed base. In this event E2V INC agrees to supply TOMO
unchanged Product in the amounts specified herein during the Initial Term.

	 
	9.	 	INTELLECTUAL PROPERTY RIGHTS AND INDEMNITY

	 
	9.1	 	Intellectual Property Right to Product or parts thereof shall remain the absolute property of
E2V INC. Similarly, TOMO shall retain full title and ownership in all Intellectual Property
Rights to the System, any TOMO confidential information, and any documents or other materials
provided to E2V INC for the purpose of supplying the Products to TOMO.

	 
	9.2	 	E2V INC will indemnify and hold harmless TOMO against all reasonable defense costs and for
reasonable damages as finally determined by a court of competent jurisdiction in any suit
brought by a third party for infringement of any Intellectual Property Right of the third
party, including but not limited to Letters Patent or Registered Design by the normal use or
sale of the Product or part thereof supplied by E2V INC to TOMO provided always that this
indemnity shall not apply to any infringement:

	 	a.	 	which is due to E2V INC having followed a design furnished or given by TOMO
or to the use of the Product or part thereof in a manner or for a purpose not
specified or disclosed to E2V INC at the time of its delivery hereunder, or in a
country not specified or disclosed at the time of its delivery with respect to any
claims of infringement made under the intellectual property laws of that country, or

	 
	 	b.	 	Which is due to the use of the Product or part thereof together with, or in
combination with, the System or any other article, material or apparatus not provided
by E2V INC,

 

 

 

and provided also that this indemnity is conditional on:

	 	a.	 	TOMO giving to E2V INC the earliest possible notice in writing of any claim
being made or action being threatened or brought against TOMO,

	 
	 	b.	 	TOMO permitting E2V INC at its own expense to conduct any litigation that may
ensue and/or all negotiations for a settlement of a claim, and

	 
	 	c.	 	TOMO not making any statement or admission regarding the claim or action
being threatened other than factual statements as requested or required by a competent
authority.

	9.3	 	Except as otherwise specified herein, the indemnity provision in Section 9.2 is given in lieu
of any or all liabilities which E2V INC might otherwise have in relation to any infringement
or alleged infringement of any patent or other right. Should any E2V INC Product be found to
infringe the Intellectual Property Rights of a third party, E2V INC shall, at its discretion,
either procure the right for E2V
INC and TOMO to continue to use such infringing Product(s), or shall offer TOMO a
non-infringing replacement product that meets TOMO’s technical requirements and
specifications. If E2V INC is unable to offer either of those options, TOMO’s obligations
under this Agreement with respect to such infringing Product(s) are excused with no further
obligation to E2V INC with respect to the infringing Product(s).

	 
	10.	 	TERMINATION FOR DEFAULT

	 
	10.1	 	Either Party may terminate the Agreement or any Purchase Order forthwith by written notice in
the event that:

	 	a.	 	any provision of this Agreement allows for such termination, or

	 
	 	b.	 	the other Party has failed to perform or observe any of the provisions of the
Agreement on its part to be performed or observed and shall, if the breach be
remediable, have failed to take reasonable steps to remedy such breach within 90
(ninety) days of receipt of written notice requiring him to do so, or

	 
	 	c.	 	The other Party shall become insolvent, or makes any arrangement with its
creditors, goes into liquidation whether voluntary or compulsory or shall have
appointed a receiver and/or manager in respect of part or the whole of its assets
except as part of a bona fide scheme of reconstruction or amalgamation.

	10.2	 	The accrued rights of either Party shall not be affected by termination for whatever cause.

	 
	11.	 	LIABILITIES FOR DEFAULT

	 
	11.1	 	The Parties shall not be liable for indirect or consequential damages (such term to include
without prejudice to the generality of the foregoing, loss of profits or third party claims)
howsoever arising in the event of any default under the Agreement or any Purchase Order.

 

 

 

	11.2	 	In the event of termination of the Agreement by TOMO as a result of breach by E2V INC
pursuant to clause 10, E2V INC’S liability shall be limited to TOMO’s reasonable excess
reprocurement costs capped to an aggregate liability payment for any and all defaults under
this Agreement, of the amount of three months of purchases by TOMO under this Agreement. The
“amount of three months of purchases by TOMO” shall be calculated by averaging the last 12
months of purchases to calculate a monthly average, and then taking that monthly average
multiplied by three. This shall be in full and final settlement of E2V INC’s liability in
termination for default. “Excess reprocurement costs” shall be defined as any costs above
and beyond the amounts TOMO would have paid to E2V INC to fulfil TOMO’s purchase obligations
under the terms of the Agreement, and could include but are not limited to NRE costs, supplier
qualification activities and costs related thereto, and expediting fees.

	 
	11.3.	 	In the event of termination of the Agreement by E2V INC as a result of breach by TOMO
pursuant to clause 10, E2V INC shall be entitled to recover payment from TOMO for all Products
delivered prior to termination and at the request of E2V INC, reasonable payment for any work
in progress under this Agreement, including payment for all Products within the fixed element
of the RPO, and for third party financial commitments entered into in reliance upon this
Agreement limited to three months of E2V INC’s purchases under any such third party
agreements. This shall be in full and final settlement of TOMO’s liability in termination for
default.

	 
	12.	 	NON ASSIGNMENT

The Parties may not assign or purport to assign any or all of its rights or obligations hereunder
without the prior written consent of the other Party, except in the instance of a change in control
or sale of substantially all the assets of a Party. Where such consent is requested, the Parties
agree that such consent shall not be unreasonably withheld. In the instance of an assignment by one
Party due to a change in control or sale of substantially all the assets of that Party, the
assigning Party agrees that the new assignee shall be bound by all of the rights and obligations of
the assigning Party under the terms of this Agreement, and further that the assigning Party shall
give the other Party no less than ninety (90) days prior written notice of such assignment.

	13.	 	NEGATION OF WAIVER

Failure of either Party at any time to enforce any of the provisions of the Agreement shall not be
construed as a waiver by such Party of any such provisions neither shall such failure in any way
affect the validity of the Agreement or any part thereof.

	14.	 	PRIOR AGREEMENTS, REPRESENTATIONS, STATEMENTS

The Parties hereto agree that the terms set out herein shall supersede all prior representations,
agreements, statements and understandings whether oral or in writing relevant to the Agreement.

 

 

 

	15.	 	SURVIVORSHIP

In the event that any portion of the Agreement is determined by a cognizant authority to be illegal
and/or invalid, the remaining portion of the document shall remain in effect provided the intent of
the Parties is not substantially changed; the illegal or invalid provision to be replaced by a
mutually agreed legal and valid provision, if necessary to continue the operability of the
Agreement.

	16.	 	AMENDMENTS

The terms of the Agreement may only be amended following the written consent of the Parties.

	17.	 	NOTICES

Any notices to be given pursuant to the Agreement shall be in writing and shall be deemed to have
been validly served:

	a.	 	15 (fifteen) days from the time of posting if sent by prepaid registered or recorded delivery
airmail post to the party to be served at its above mentioned address or such other address as
it may from time to time have communicated to the other as its address for service, or

	 
	b.	 	At the time of completion of the transmission if sent by telefax during the normal business
hours of the party to be served (or on the next following business day of such party if not
sent during such business hours) provided always that in the case of service of notice by
telefax a further copy of such notice shall promptly have been sent by post in the aforesaid
manner to the party to be served.

	18.	 	HEADINGS

The clause headings hereof are for reference purposes only and shall not affect the construction of
the Agreement.

	19.	 	CONFIDENTIALITY

The Parties acknowledge that the Agreement is confidential and undertake not to disclose its
contents to any third party without the express permission of the other Party. The
Confidentiality Agreement entered into by the Parties as of July 27, 2006 shall remain in full
force and effect for the duration of this Agreement, and shall remain in effect for two years after
the expiration or termination of this Agreement.

	20.	 	LAW AND ARBITRATION

This agreement shall be governed by and the rights and obligations of the Parties shall be
construed in all respects in accordance with the laws of the State of New York, USA, excluding its
conflicts of laws provisions. Any controversy, dispute or claim arising out of or relating to this
agreement shall be finally determined by arbitration under the international arbitration rules of
the American Arbitration Association. The number of arbitrators shall be three. The place of
arbitration shall be New York, New York. The language of the arbitration shall be English. The
arbitrators shall not be empowered to award punitive or exemplary damages.

 

 

 

IN WITNESS THEREOF the parties hereto have caused this Agreement to be signed by their duly
authorised representatives.

	 	 	 
	Signed for and on behalf of

E2V TECHNOLOGIES (UK) LIMITED
	 	 
	 
	 	 
	/s/ Charlotte Parmenter
 

Name: Charlotte Parmenter

	 	 
	Position: Commercial Manager
	 	 
	 
	 	 
	Date: December 19, 2008
	 	 
	 
	 	 
	Signed for and on behalf of

E2V INC
	 	 
	 
	 	 
	/s/ Robert E. Calabrese
 

Name: Robert E. Calabrese

Position: Sr. Vice President, Sales

	 	 
	 
	 	 
	Date: December 22, 2008
	 	 
	 
	 	 
	Signed for and on behalf of

TOMOTHERAPY INCORPORATED
	 	 
	 
	 	 
	/s/ Stephen C. Hathaway
 

Name: Stephen C. Hathaway

Position: Chief Financial Officer

	 	 
	 
	 	 
	Date: December 18, 2008
	 	 

 

 

 

EXHIBIT A

In accordance with Section 3.5 and 3.7, E2V INC and E2V LTD reserve the right to adjust pricing
against anticipated quantity for that Product Item in line with the pricing breaks contained herein
to reflect the sums due for the lower quantity purchased throughout the Initial Term.

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Total	 	 	 	 	 	 	 	 	 	 	Total	 	 	 	 
	 	 	Quantity	 	 	Unit Price	 	 	 	 	 	 	Quantity	 	 	Unit Price	 
	e2v P/N	 	Supplied	 	 	(GBP)	 	 	e2v P/N	 	 	Supplied	 	 	(GBP)	 
	[ * ]
	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 
	[ * ]
	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 
	[ * ]
	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 
	[ * ]
	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 
	[ * ]
	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 	 	 	[ * ]	 

 

 

 

Exhibit B

Standard Conditions of Warranty for e2v Products

The following Standard Conditions of Warranty are issued in conjunction with e2v General Terms
and Conditions of Sale for the Purchaser’s benefit and contain important information relating to
the Warranty in respect of the Product and  a Return Procedure. Please read this carefully.

	1.	 	CONDITION

Except where otherwise agreed in writing, the Product shall be subject to the following conditions
of warranty.

Each Product for which a warranty is offered is guaranteed against defects in workmanship and
materials and designed to perform to its specification when operated in accordance with e2v’s
instructions. The warranty applicable to each Product is defined in a warranty code contained in
e2v’s written quotation and confirmed on e2v’s written order acknowledgement.

A warranty code is comprised of a letter and one or two groups of numbers.

The letter gives the total warranty period commencing from the date of despatch of the Product
from e2v, subject to the group or groups of numbers.

	A 	 	indicates 2 years.

	 
	B 	 	indicates 18 months.

	 
	C 	 	indicates that the number following gives the warranty period in months.

	 
	E 	 	indicates 1 year.

	 
	G 	 	indicates 3 years.

	 
	H 	 	indicates 4 years.

	 
	J 	 	indicates that the number following gives the warranty period in months.

Where
the letter is followed by two groups of numbers (e.g. A100/1000):

	a.	 	the first group (e.g.
A100/1000) gives the filament or high tension (HT) life in hours
within which the Product may, at e2v’s sole option, be repaired or replaced free of charge or
credited in full; except for J terms, which gives this period in months.

	 
	b.	 	the second group (e.g.
A100/1000) gives the total warranted number of filament or HT life
in hours; except for J terms, which gives this period in months. For a Product failing with a
filament or HT life in excess of the hours specified by the first group of numbers (100) but
less than the total number of hours/months given by the second group (1000), repairs,
replacements or credit will be given on a pro-rata basis, determined by the ratio of the
unused portion of the total warranted hours to the second group of numbers, provided that the
period indicated by the letter (A = 2 years) has not expired.

Where the letter is preceded by a number (e.g. 6C24), this indicates an agreed shelf life before
use. Therefore, the warranty period begins as soon as the product is used, or at latest, six
months after delivery of the product by e2v.

Where the letter is followed by one group of numbers (e.g. C12), this gives the total warranted
period either in months for ‘C’ terms or in filament or HT hours for other terms during which, at
e2v’s sole option, the Product will be repaired, or full replacement or credit will be given.

In the unlikely event that a quotation or acknowledgement does not contain a warranty coding for
your specific Product, or in the event that you require clarification of a warranty coding, please
contact the appropriate e2v Sales Department Personnel.

	2.	 	CLAIMS

	2.1	 	Damage in Transit

	a.	 	Each Product is inspected by e2v prior to despatch and should be examined by the Purchaser
immediately on receipt.

	 
	b.	 	The carton or packing crate should be examined for signs of damage and the Carrier’s note
endorsed accordingly. If inspection is not possible at this stage the item should be signed
for as “unexamined”. The Product must then be unpacked with minimum delay and, after
inspection for damage to its glasswork or internal structure, an electrical test applied.
Where a static test is impracticable, a functional test in its intended equipment is
recommended.

	 
	c.	 	Where damage in transit is suspected, the original packing materials should be retained to
return the product. If the Product has been damaged in transit, and if e2v has arranged the
insurance cover on behalf of the Purchaser, the Purchaser should, within 7 days of receipt of
the Product, either (a) inform the nearest Lloyds Representative, or (b) notify e2v, who will
file an insurance claim. If insurance has been arranged by the Purchaser, then the Purchaser
should deal with this in his usual way.

	2.2	 	Conditions of Warranty

This
warranty is valid only if the following conditions are met:

	a.	 	The Product has been supplied directly by e2v or via a distributor, representative or other
selling medium authorised by e2v.

	 
	b.	 	The Product has been operated within its specification and in accordance with e2v instructions.

	 
	c.	 	The Product has not been subjected to any accident, abuse, alteration, misuse or neglect in
storage, transportation, handling or use.

	 
	d.	 	The return procedure specified in Paragraph 3 below is followed.

	 
	e.	 	The decision of e2v on the cause of failure and on the value and form of any applicable
allowances is accepted by the Purchaser.

	 
	f.	 	Right of access to equipment for the purpose of checking operating conditions is granted to
any representative of e2v where e2v may so require.

	 
	g.	 	e2v is notified within 30 days of the Product failure.

	 
	h.	 	The Product is withdrawn from service as soon as possible after the alleged failure has
occurred.

	2.3	 	Limitation of Liability

Unless expressly stated in a separate written agreement between e2v and the Purchaser, this
warranty defines fully the extent of e2v’s liability for the Product and shall be in lieu of any
warranty condition or liability express or implied by law or otherwise, including warranties of
merchantability and fitness for a particular purpose which are hereby expressly excluded. The sole
obligation of e2v under this warranty is to carry out repairs, supply replacement Products or give
credit as specified herein. In no event shall e2v be liable for consequential damage howsoever
arising. In the event of any conflict between the original English version and the French and
German or other translations of this document, the English version shall prevail.

			
	 	 	 
	ã e2v technologies plc and subsidiaries 2006, 2008
	 	11555A-6, page 1

 

 

 

	3.	 	RETURN PROCEDURE

The return procedure specified below must be followed if returning a product under warranty:

	3.1	 	A Product Service Report Form, which is despatched with the product, must be completed
giving all information requested and noting, in particular, any unusual occurrences before or
at the time of failure. The Form must be returned with the returned product.

	 
	3.2	 	The returned product should be packed in the same manner as originally, preferably by use
of the same packaging materials. If the purchaser cannot provide suitable packing it can be
provided at the purchaser’s expense.

	 
	3.3	 	The returned product must be insured and carriage paid by the Purchaser, and e2v accepts no
responsibility for loss of, or damage to, a returned product during transit.

	 
	3.4	 	If repair or replacement is offered, the Purchaser will be notified in writing and the
product will be despatched, carriage and insurance paid, to destinations within the United
Kingdom or to a suitable United Kingdom port of embarkation in the case of overseas
Purchasers.

	 
	3.5	 	Where credit is offered in settlement of a claim such credit shall, in all cases, unless
otherwise agreed, be based on the FCA (UK Port or Airport) INCOTERMS 2000 selling price of the
product for overseas Purchasers, or on the net delivered price for Purchasers within the
United Kingdom. If the returned Product is not defective and is still serviceable, it will be
returned at the Purchaser’s expense.

	 
	3.6	 	It may be necessary for an inoperative product to be dismantled by e2v to determine the
cause of failure and permission for this to be done is granted automatically by the Purchaser
in returning the Product. An inoperative product will only be returned to the Purchaser at
his expense if no repair, credit or replacement can be allowed. Where credit or replacement
is allowed, the returned Product shall become the property of e2v.

	4.	 	RE-WARRANTY

Products that have been repaired or replaced under warranty will be re-warranted to the end of the
original period of warranty of the repaired or replaced product or for three months, whichever is
longer. The expiry of the original period of warranty for the purposes of re-warranty will be
extended to take account of the duration of the interruption of use as a result of the failure under
warranty.Filed by Bowne Pure Compliance

Exhibit 10.2

Confidential treatment has been requested for portions of this exhibit. The copy filed herewith
omits the information subject to the confidentiality request. Omissions are designated as [  *  ].
A complete version of this exhibit has been filed separately with the Securities and Exchange
Commission.

Agreement No. 98-0228B

AMENDMENT TO LICENSE AGREEMENT 98-0228

This Amendment is made effective as of the 16th day of December, 2008, by and between Wisconsin
Alumni Research Foundation (“WARF”), a nonstock, nonprofit Wisconsin corporation, and TomoTherapy
Incorporated (“TomoTherapy”), a corporation organized and existing under the laws of Wisconsin.

WITNESSETH

WHEREAS, WARF and TomoTherapy entered into license agreement 98-0228 made effective February
22, 1999, as amended April 16, 2007, (collectively, the “Agreement”); and

WHEREAS, WARF and TomoTherapy desire to amend the Agreement to modify and clarify certain
rights and obligations under the Agreement.

NOW THEREFORE, in consideration of the mutual covenants and agreements set forth below and in
the Agreement, the parties covenant and agree as follows:

	1.	 	Appendix B of the Agreement is hereby deleted and replaced with the attached, revised
Appendix B.

	2.	 	The following is hereby added after the last sentence of Section 2A of the Agreement as a new
paragraph:

“First Right of Refusal. WARF hereby grants to TomoTherapy a first right of refusal
to additional fields not included in the Licensed Field. Such right may be renewable as described
in this Section 2A. If an interested third party desires to license the Licensed Patents from WARF
in a field(s) of use that falls outside of the Licensed Field, WARF shall notify TomoTherapy of
such and TomoTherapy may opt to add such noticed additional field(s) to the Licensed Field.
TomoTherapy’s first right of refusal shall apply to each opportunity that arises for WARF to
license any additional field(s) not included in the Licensed Field that has not otherwise been
licensed to TomoTherapy or a prior interested third party. In order to add such noticed additional
field(s), TomoTherapy must, within eight (8) weeks of receiving such notice, both (1) notify WARF
in writing that it is exercising its rights under this Section 2A, indicating to which noticed
additional field(s) TomoTherapy wishes to obtain rights; and (2) provide WARF with an acceptable
Development Plan in the same form as Appendix E, describing the steps that TomoTherapy believes are
necessary to provide products to the commercial market in the requested fields using the Licensed
Patents. If such notification and Development Plan are not provided within eight (8) weeks,
TomoTherapy’s then current right to include such noticed additional field(s) shall terminate, and
WARF may freely license such noticed additional field(s) to the interested third party. Upon
WARF’s receipt of notice and a Development Plan reasonably acceptable to WARF, WARF and TomoTherapy
shall enter into good faith negotiations regarding the terms governing the license for said
additional fields. WARF and TomoTherapy shall have three (3) months from the date that WARF
receives notice pursuant to this Section 2A, to negotiate such a license. If WARF and TomoTherapy
fail to enter a license within such time period, WARF shall be free to license such noticed fields
to the interested third party.

 

 

 

	3.	 	Section 3D(i) of the Agreement is hereby deleted and replaced with the following:

“(i) In addition to the Section 3B license fee, TomoTherapy agrees to pay to WARF as
“earned royalties” a royalty per Therapy Unit and Upgrade or Option sold or leased by
TomoTherapy at a rate determined in accordance with the following tables:

	 	 	 
	Royalty per Therapy Unit sold:	 	For the period:
	[ * ]% of Selling Price

	 	Starting on the effective date of this
Amendment and ending [ * ]
	[ * ]% of Selling Price

	 	Starting on [ * ] and ending on [ * ]
	[ * ]% of Selling Price

	 	Starting on [ * ] and through the date that
no Licensed Patent remains an enforceable
patent

	 	 	 
	Royalty per Option or Upgrade sold:	 	For the period:
	[ * ]% of the Selling Price of a
Option or Upgrade

	 	Starting on the effective date of
this Amendment and through the date
that no Licensed Patent remains an
enforceable patent

	4.	 	TomoTherapy agrees to pay to WARF [ * ] percent ([ * ]%) of the actual costs incurred by WARF
starting on the effective date of this Amendment for filing, prosecuting and maintaining the
Licensed Patent with WARF Ref. No. P01199US, “Radiation Detector with Laterally Acting
Converters” and its foreign counterparts, which TomoTherapy requests WARF to file.

	5.	 	Section 9A of the Agreement is hereby deleted and replaced with the following:

“A. WARF intends to protect the Licensed Patents against infringers or otherwise act to
eliminate infringement, when, in WARF’s sole judgment, such action may be reasonably
necessary, proper, and justified. In the event that TomoTherapy believes there is
infringement of any Licensed Patent under this Agreement which is to TomoTherapy’s
substantial detriment, TomoTherapy shall provide WARF with written notice that such
infringement is occurring including reasonable evidence of the infringement. WARF shall have
the right to determine the best course of action to resolve such infringement, however, in
no event will WARF grant a license to any such alleged infringer to practice the inventions
of the Licensed Patents thereafter without a sublicense directly from TomoTherapy. Upon
request by WARF, TomoTherapy shall take action, join in an action, and otherwise provide
WARF with such assistance and information as may be useful to

 

 

 

WARF
in connection with WARF’s
taking such action (if the cause of action arose during the term of this Agreement and WARF
reimburses TomoTherapy for TomoTherapy’s reasonable out-of-pocket expenses). Any recovery or
damages for infringement or license fees or royalties obtained through any settlement of
infringement claims, except enhanced damages, derived through WARF taking such action shall
be applied as follows: (a) first, to WARF to reimburse WARF for expenses incurred in
litigation or negotiating a
settlement, including reasonable attorneys’ fees, (b) second, to TomoTherapy to reimburse
TomoTherapy for its reasonable expenses in assisting with same, including reasonable
attorneys’ fees, and (c) the balance of any recovery or damages shall be divided [ * ]
percent ([ * ]%) to TomoTherapy and [ * ] percent ([ * ]%) to WARF. If WARF does not take
action to abate the infringement of the Licensed Patents within [ * ] months of receiving
the notice described above, TomoTherapy may request that WARF do so and WARF’s compliance
with TomoTherapy’s request will not be unreasonably withheld, provided TomoTherapy
reimburses WARF each month for [ * ] percent ([ * ]%) of WARF’s actual incurred expenses in
taking such action. Such expenses may be billed by WARF as frequently as monthly and shall
be paid by TomoTherapy to WARF on a net thirty (30) days basis. Late payments shall be
subject to the interest provisions set forth in Section 3F(i) for late payments. TomoTherapy
shall be reimbursed for its contribution to the cost of litigation or settlement from the
proceeds of such action as described in this Section 9A. TomoTherapy shall not have the
right to bring any infringement action or enforce the Licensed Patents without WARF’s prior,
written consent.”

	5.	 	The following sentence is hereby added as the last sentence of Paragraph “E” of Appendix A to
the Agreement:

“The Licensed Field explicitly excludes medical applications using Ions.”

	6.	 	Paragraph “B” of Appendix A of the Agreement is hereby amended to read as such:

“B. “Products” and “Product Unit” shall mean any item or unit that employs or is in any way
produced by the practice of an invention claimed in the Licensed Patents or that otherwise
constitutes infringement of any claims of the Licensed Patents. Products and Product Units
shall be classified either as Therapy Units, Options or Upgrades.

	7.	 	Paragraphs “F”, “G”, “H” and “I” are hereby added to Appendix A of the Agreement:

“F. “Option” or “Upgrade” shall mean any item or unit that employs or is produced by the
practice of an invention claimed in the Licensed Patents or otherwise constitutes
infringement of any claims of the Licensed Patents and is not a Therapy Unit.”

“G. “Therapy Unit” shall mean any item or unit capable on its own of producing radiation for
the purposes of diagnostics, imaging, or therapy and that employs or is produced by the
practice of an invention claimed in the Licensed Patents or would otherwise constitute
infringement of any claims of the Licensed Patents.”

 

 

 

“H. “Selling Price” shall mean, in the case of Products that are sold or leased, the invoice
price to the end user of Products (regardless of uncollectible accounts) less any shipping
costs, allowances because of returned Products, sales taxes, software or hardware
non-obsolescence packages (that do not contain the inventions of the Licensed Patents), or
any amounts attributable to the purchase of service plans. The “Selling Price” for a
Product that is transferred to a third party for promotional
purposes without charge or at a discount shall be the average invoice price to the end user
of that type of Product during the applicable calendar quarter.”

“I. “Ion” shall mean an atom or a group of atoms that has acquired a net electric charge by
gaining or losing one or more electrons.”

	8.	 	TomoTherapy agrees to pay to WARF an amendment fee of $[ * ], and patent expense
reimbursement of $[ * ] for U.S. and foreign patent prosecution expenses incurred up to the
effective date of this Amendment within thirty (30) days of Licensee’s execution of this
Amendment.

	9.	 	Except as otherwise provided in this Amendment, all terms and conditions previously set forth
in the Agreement shall remain in effect as set forth therein and all defined terms used in
this Amendment shall have the same meaning as indicated in the Agreement. In the event that
this Amendment and the Agreement are inconsistent, the terms and provisions of this Amendment
shall supercede the terms and provisions of the Agreement, but only to the extent necessary to
satisfy the purpose of this Amendment. Each party hereto represents to the other that it has
the full authority to execute, deliver and perform this Amendment in accordance with its
terms.

 

 

 

IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment on the dates
indicated below.

	 	 	 	 	 	 	 
	WISCONSIN ALUMNI RESEARCH FOUNDATION	 	 	 	 
	 
	 	 	 	 	 	 
	By:

	 	/s/ Craig Christianson
	 	 	 	Date: 12/23/08
	 

	 	 

Craig Christianson,
 Director of Licensing
	 	 	 	 
	 
	 	 	 	 	 	 
	TOMOTHERAPY INCORPORATED	 	 	 	 
	 
	 	 	 	 	 	 
	By:

	 	/s/ Frederick A. Robertson
 
Name & Title: Frederick A.
Robertson,
 Chief Executive Officer
	 	 	 	Date: 12/18/08 

WARF Ref: Swerdloff — P91009US

 

 

 

Appendix B

Licensed Patents

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	REFERENCE	 	 	 	PATENT	 	 	ISSUE	 	 	APPLICATION	 
	NUMBER	 	COUNTRY	 	NUMBER	 	 	DATE	 	 	SERIAL NUMBER	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	METHOD AND APPARATUS FOR RADIATION THERAPY (SWERDLOFF Stuart J, MACKIE Thomas R, HOLMES Timothy
W )
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P91009US
	 	UNITED STATES	 	 	5,317,616	 	 	 	5/31/94	 	 	 	 	 
	P91009AU
	 	AUSTRALIA	 	 	661,640	 	 	 	12/12/95	 	 	 	 	 
	P91009BE
	 	BELGUIM	 	 	0561533	 	 	 	 	 	 	 	93301672.7	 
	P91009CA
	 	CANADA	 	 	2091275	 	 	 	 	 	 	 	2091275	 
	P91009DE
	 	GERMANY	 	 	69319010.9	 	 	 	 	 	 	 	 	 
	P91009EP
	 	EPO	 	 	 	 	 	 	 	 	 	 	10/715986	 
	P91009FR
	 	FRANCE	 	 	0561533	 	 	 	 	 	 	 	93301672.7	 
	P91009GB
	 	GREAT BRITAIN	 	 	0561533	 	 	 	 	 	 	 	93301672.7	 
	P91009IL
	 	ISRAEL	 	 	104896	 	 	 	5/1/97	 	 	 	 	 
	P91009JP
	 	JAPAN	 	 	3522300	 	 	 	 	 	 	 	5-58983	 
	P91009KR
	 	SOUTH KOREA	 	 	10-273183	 	 	 	 	 	 	 	4146/1993	 
	P91009MX
	 	MEXICO	 	 	 	 	 	 	 	 	 	 	931495	 
	P91009NL
	 	NETHERLANDS	 	 	0561533	 	 	 	 	 	 	 	93301672.7	 
	P91009NZ
	 	NEW ZEALAND	 	 	247042	 	 	 	6/4/96	 	 	 	 	 

 

 

 

RADIATION THERAPY SYSTEM WITH CONSTRAINED ROTATIONAL FREEDOM (SWERDLOFF Stuart J, MACKIE Thomas
R, HOLMES Timothy W)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P92135US
	 	UNITED STATES	 	 	 	 	 	 	 	 	 	 	08/071742	 
	P92135EP
	 	EPO	 	 	0703805	 	 	 	3/25/98	 	 	 	94920124.8	 
	P92135DE
	 	GERMANY	 	 	69409234.7	 	 	 	3/25/98	 	 	 	94920124.8	 
	P92135FR
	 	FRANCE	 	 	 	 	 	 	 	 	 	 	94920124.8	 
	P92135GB
	 	GREAT BRITAIN	 	 	 	 	 	 	 	 	 	 	94920124.8	 
	P92135IL
	 	ISRAEL	 	 	 	 	 	 	 	 	 	 	109960	 
	P92135JP
	 	JAPAN	 	 	8-511452	 	 	 	12/03/96	 	 	 	 	 
	P92135NL
	 	NETHERLANDS	 	 	 	 	 	 	 	 	 	 	94920124.8	 
	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 

RADIATION THERAPY SYSTEM (SWERDLOFF Stuart J, MACKIE Thomas R, HOLMES Timothy W)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P92136EP
	 	EPO	 	 	 	 	 	 	 	 	 	 	97113658.5	 
	P92136NL
	 	NETHERLANDS	 	 	081006	 	 	 	9/27/00	 	 	 	081006	 
	P92136GB
	 	GREAT BRITAIN	 	 	081006	 	 	 	9/27/00	 	 	 	081006	 
	P92136FR
	 	FRANCE	 	 	081006	 	 	 	9/27/00	 	 	 	081006	 
	P92136DE
	 	GERMANY	 	 	69416587.5	 	 	 	9/27/00	 	 	 	081006	 

 

 

 

RADIATION THERAPY SYSTEM WITH CONSTRAINED ROTATIONAL FREEDOM (SWERDLOFF Stuart J, MACKIE Thomas
R, HOLMES Timothy W)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P92137DE
	 	GERMANY	 	 	69416587.5	 	 	 	2/17/99	 	 	 	94920125.5	 
	P92137EP
	 	EPO	 	 	0702839	 	 	 	2/17/99	 	 	 	94920125.5	 
	P92137FR
	 	FRANCE	 	 	0702839	 	 	 	2/17/99	 	 	 	94920125.5	 
	P92137GB
	 	GREAT BRITAIN	 	 	0702839	 	 	 	2/17/99	 	 	 	94920125.5	 
	P92137IL
	 	ISRAEL	 	 	 	 	 	 	 	 	 	 	109961	 
	P92137JP
	 	JAPAN	 	 	8-511453	 	 	 	12/03/96	 	 	 	 	 
	P92137NL
	 	NETHERLANDS	 	 	0702839	 	 	 	2/17/99	 	 	 	94920125.5	 

RADIATION THERAPY SYSTEM (SWERDLOFF Stuart J, MACKIE Thomas R, HOLMES Timothy W)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P92138EP
	 	EPO	 	 	0810005	 	 	 	9/27/00	 	 	 	97113657.7	 
	P92138GB
	 	GREAT BRITAIN	 	 	0810005	 	 	 	9/27/00	 	 	 	97113657.7	 
	P92138FR
	 	FRANCE	 	 	0810005	 	 	 	9/27/00	 	 	 	97113657.7	 
	P92138NL
	 	NETHERLANDS	 	 	 	 	 	 	 	 	 	 	97113657.7	 
	P92138DE
	 	GERMANY	 	 	69426036.6	 	 	 	9/27/00	 	 	 	97113657.7	 

DYNAMIC COLLIMATOR FOR RADIATION THERAPY (SWERDLOFF Stuart J, MACKIE Thomas R, HOLMES Timothy
W, RECKWERDT Paul J)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P92138US
	 	UNITED STATES	 	 	5,442,675	 	 	 	8/15/95	 	 	 	 	 

VERIFICATION SYSTEM FOR RADIATION THERAPY (SWERDLOFF Stuart J, MACKIE Thomas R, HOLMES Timothy
W)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P92140US
	 	UNITED STATES	 	 	5,394,452	 	 	 	2/28/95	 	 	 	 	 
	P92140IL
	 	ISRAEL	 	 	 	 	 	 	 	 	 	 	109962	 

 

 

 

MULTI-LEAF RADIATION ATTENUATOR FOR RADIATION THERAPY (SWERDLOFF Stuart J, MACKIE Thomas R,
HOLMES Timothy W)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P92142US
	 	UNITED STATES	 	 	5,351,280	 	 	 	9/27/94	 	 	 	 	 
	P92142DE
	 	GERMANY	 	 	69410463.9	 	 	 	5/20/98	 	 	 	94920712.0	 
	P92142EP
	 	EPO	 	 	0703806	 	 	 	5/20/98	 	 	 	94920712.0	 
	P92142FR
	 	FRANCE	 	 	0703806	 	 	 	5/20/98	 	 	 	94920712.0	 
	P92142GB
	 	GREAT BRITAIN	 	 	0703806	 	 	 	5/20/98	 	 	 	94920712.0	 
	P92142IL
	 	ISRAEL	 	 	 	 	 	 	 	 	 	 	109962	 
	P92142JP
	 	JAPAN	 	 	3553943	 	 	 	5/14/04	 	 	 	7-502084	 
	P92142NL
	 	NETHERLANDS	 	 	0703806	 	 	 	5/20/98	 	 	 	94920712.0	 

MULTI-LEAF RADIATION ATTENUATOR FOR RADIATION THERAPY WITH VERIFICATION SYSTEM (SWERDLOFF
Stuart J, MACKIE Thomas R, HOLMES Timothy W)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P92143EP
	 	EPO	 	 	0832669	 	 	 	8/18/04	 	 	 	97100108.6	 
	P92143NL
	 	NETHERLANDS	 	 	0773042	 	 	 	10/6/04	 	 	 	97100108.6	 
	P92143GB
	 	GREAT BRITAIN	 	 	0773042	 	 	 	10/6/04	 	 	 	97100108.6	 
	P92143FR
	 	FRANCE	 	 	0773042	 	 	 	10/6/04	 	 	 	97100108.6	 
	P92143DE
	 	GERMANY	 	 	69434055.6	 	 	 	8/18/04	 	 	 	97100108.6	 

MULTI-LEAF RADIATION ATTENUATOR FOR RADIATION THERAPY (SWERDLOFF Stuart J, MACKIE Thomas R,
HOLMES Timothy W)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P92144EP
	 	EPO	 	 	0832669	 	 	 	8/18/04	 	 	 	97118687.9	 
	P92144NL
	 	NETHERLANDS	 	 	0832669	 	 	 	8/18/04	 	 	 	97118687.9	 
	P92144GB
	 	GREAT BRITAIN	 	 	0832669	 	 	 	8/18/04	 	 	 	97118687.9	 
	P92144FR
	 	FRANCE	 	 	0832669	 	 	 	8/18/04	 	 	 	97118687.9	 
	P92144DE
	 	GERMANY	 	 	69433954.7	 	 	 	8/18/04	 	 	 	97118687.9	 

 

 

 

DELIVERY MODIFICATION SYSTEM FOR RADIATION THERAPY (FITCHARD Edward E, OLIVERA Gustavo H,
RECKWERDT Paul J, MACKIE Thomas R)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P92220JP
	 	JAPAN	 

METHOD AND APPARATUS FOR RADIATION THERAPY (SWERDLOFF Stuart J, MACKIE Thomas R, HOLMES Timothy
W)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P94001US
	 	UNITED STATES	 	 	5,528,650	 	 	 	6/18/96	 	 	 	 	 

DELIVERY MODIFICATION SYSTEM FOR RADIATION THERAPY (FITCHARD Edward E, OLIVERA Gustavo H,
RECKWERDT Paul J, MACKIE Thomas R)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P95061EP
	 	EPO	 	 	0810005	 	 	 	9/27/00	 	 	 	97113657.7	 

RADIATION THEATMENT PLANNING METHOD AND APPARATUS (HOLMES Timothy W)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P95083US
	 	UNITED STATES	 	 	5,647,663	 	 	 	7/15/97	 	 	 	 	 

METHOD OF REGISTERING A RADIATION TREATMENT PLAN TO A PATIENT (RECKWERDT Paul J, MACKIE Thomas
R)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P95107US
	 	UNITED STATES	 	 	5,673,300	 	 	 	9/30/97	 	 	 	 	 
	P95107CA
	 	CANADA	 	 	 	 	 	 	 	 	 	 	2,207,539	 
	P95107EP
	 	EPO	 	 	0812605	 	 	 	8/18/04	 	 	 	97303909.2	 
	P95107JP
	 	JAPAN	 	 	 	 	 	 	 	 	 	 	09-167979	 
	P95107FR
	 	FRANCE	 	 	0812605	 	 	 	8/18/04	 	 	 	97303909.2	 
	P95107DE
	 	GERMANY	 	 	0812605	 	 	 	8/18/04	 	 	 	97303909.2	 
	P95107GB
	 	GREAT BRITAIN	 	 	0812605	 	 	 	8/18/04	 	 	 	97303909.2	 
	P95107IT
	 	ITALY	 	 	0812605	 	 	 	8/18/04	 	 	 	97303909.2	 
	P95107NL
	 	NETHERLANDS	 	 	0812605	 	 	 	8/18/04	 	 	 	97303909.2	 

 

 

 

RADIATION THERAPY SYSTEM WITH CONSTRAINED ROTATIONAL FREEDOM (SWERDLOFF Stuart J, MACKIE Thomas
R, HOLMES Timothy W)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P95141US
	 	UNITED STATES	 	 	5,548,627	 	 	 	8/20/96	 	 	 	 	 

DYNAMIC BEAM FLATTENING APPARATUS FOR RADIATION THERAPY (SWERDLOFF Stuart J, MACKIE Thomas R,
HOLMES Timothy W)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P95201US
	 	UNITED STATES	 	 	5,625,663	 	 	 	4/29/97	 	 	 	 	 

INTERFACE FOR RADIATION THERAPY MACHINE (SWERDLOFF Stuart J, MACKIE Thomas R, HOLMES Timothy
W)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P95202US
	 	UNITED STATES	 	 	5,661,773	 	 	 	8/26/97	 	 	 	 	 

RADIATION THERAPY SYSTEM WITH CONSTRAINED ROTATIONAL FREEDOM (SWERDLOFF Stuart J, MACKIE Thomas
R, HOLMES Timothy W)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P95254US
	 	UNITED STATES	 	 	5,724,400	 	 	 	3/3/98	 	 	 	 	 

METHOD AND APPARATUS FOR CALIBRATION OF RADIATION THERAPY EQUIPMENT AND VERIFICATION OF
RADIATION TREATMENT (MACKIE Thomas R, RECKWERDT Paul J, MCNUTT Todd R)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P98069US
	 	UNITED STATES	 	 	6,345,114	 	 	 	2/5/02	 	 	 	 	 

METHOD AND APPARATUS FOR CALIBRATION OF RADIATION THERAPY EQUIPMENT AND VERIFICATION OF
RADIATION TREATMENT (MACKIE Thomas R, RECKWERDT Paul J, MCNUTT Todd R)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P98167IL
	 	ISRAEL           	 	 	 	 	 	 	 	 	 	 	122219	 

 

 

 

METHOD USING POST-PATIENT RADIATION MONITOR TO VERIFY ENTRANCE RADIATION AND DOSE IN A
RADIATION THERAPY MACHINE (OLIVERA Gustavo H, KAPATOES Jeffrey M, MACKIE Thomas R, RECKWERDT Paul
J, FITCHARD Edward E, ZACHMAN Julie C)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P99030US
	 	UNITED STATES	 	 	6438202	 	 	 	8/20/02	 	 	 	09/555468	 
	P99030WO
	 	W.I.P.O.	 	 	 	 	 	 	 	 	 	US99/17673	 
	P99030EP
	 	EPO	 	 	 	 	 	 	 	 	 	 	99940880.0	 
	P99030AU
	 	AUSTRALIA	 	 	747524	 	 	 	8/29/02	 	 	 	54651/99	 
	P99030CA
	 	CANADA	 	 	2339270	 	 	 	10/7/03	 	 	 	2339270	 
	P99030FR
	 	FRANCE	 	 	1100587	 	 	 	8/3/07	 	 	 	99940880.0	 
	P99030DE
	 	GERMANY	 	 	 	 	 	 	8/3/07	 	 	 	99940880.0	 
	P99030GB
	 	GREAT BRITAIN	 	 	 	 	 	 	 	 	 	 	99940880.0	 
	P99030IL
	 	ISRAEL	 	 	 	 	 	 	 	 	 	 	141203	 
	P99030JP
	 	JAPAN	 	 	33775992	 	 	 	3/3/06	 	 	 	2000-563348	 
	P99030KR
	 	KOREA	 	 	 	 	 	 	 	 	 	 	2001-7001600	 
	P99030MX
	 	MEXICO	 	 	240460	 	 	 	9/22/06	 	 	 	2001-001371	 
	P99030NL
	 	NETHERLANDS	 	 	 	 	 	 	 	 	 	 	99940880.0	 
	P99030NZ
	 	NEW ZEALAND	 	 	509666	 	 	 	3/29/04	 	 	 	509666	 
	P99030SE
	 	SWEDEN	 	 	 	 	 	 	 	 	 	 	99940880.0	 

 

 

 

DELIVERY MODIFICATION SYSTEM FOR RADIATION THERAPY (FITCHARD Edward E, OLIVERA Gustavo H,
RECKWERDT Paul J, MACKIE Thomas R)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P99031US
	 	UNITED STATES	 	 	6385286	 	 	 	 	 	 	 	09/582538	 
	P99031AU
	 	AUSTRALIA	 	 	746987	 	 	 	8/22/08	 	 	 	54654/99	 
	P99031CA
	 	CANADA	 	 	2339497	 	 	 	10/7/03	 	 	 	2339497	 
	P99031DE
	 	GERMANY	 	 	1102611	 	 	 	5/3/06	 	 	 	99940882.6	 
	P99031EP
	 	EPO	 	 	1102611	 	 	 	5/3/06	 	 	 	99940882.6	 
	P99031FR
	 	FRANCE	 	 	1102611	 	 	 	5/3/06	 	 	 	99940882.6	 
	P99031GB
	 	GREAT BRITAIN	 	 	1102611	 	 	 	5/3/06	 	 	 	99940882.6	 
	P99031IL
	 	ISRAEL	 	 	141204	 	 	 	11/20/07	 	 	 	141204	 
	P99031IT
	 	ITALY	 	 	1102611	 	 	 	5/3/06	 	 	 	99940882.6	 
	P99031JP
	 	JAPAN	 	 	3749119	 	 	 	12/9/05	 	 	 	2000-563350	 
	P99031KR
	 	KOREA	 	 	 	 	 	 	 	 	 	 	2001-7001598	 
	P99031NL
	 	NETHERLANDS	 	 	1102611	 	 	 	5/3/06	 	 	 	99940882.6	 
	P99031NZ
	 	NEW ZEALAND	 	 	509667	 	 	 	12/8/03	 	 	 	509667	 
	P9903MX
	 	MEXICO	 	 	222903	 	 	 	9/23/04	 	 	 	2001-001368	 
	P99031SE
	 	SWEDEN	 	 	1102611	 	 	 	5/3/06	 	 	 	99940882.6	 
	P99031WO
	 	W.I.P.O	 	 	 	 	 	 	 	 	 	US99/17675	 

DELIVERY MODIFICATION SYSTEM FOR RADIATION THERAPY (FITCHARD Edward E, OLIVERA Gustavo H,
RECKWERDT Paul J, MACKIE Thomas R)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P99354EP
	 	EPO	 	 	 	 	 	 	 	 	 	 	05001901.7	 
	P99354IL
	 	ISRAEL	 	 	 	 	 	 	 	 	 	 	173494	 

 

 

 

DELIVERY MODIFICATION SYSTEM FOR RADIATION THERAPY (FITCHARD Edward E, OLIVERA Gustavo H,
RECKWERDT Paul J, MACKIE Thomas R)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P99355JP
	 	JAPAN	 	 	 	 	 	 	 	 	 	 	 	 

DELIVERY MODIFICATION SYSTEM FOR RADIATION THERAPY (FITCHARD Edward E, OLIVERA Gustavo H,
RECKWERDT Paul J, MACKIE Thomas R)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P99357EP
	 	EPO	 	 	 	 	 	 	 	 	 	 	 	 

METHOD USING POST-PATIENT RADIATION MONITOR TO VERIFY ENTRANCE RADIATION AND DOSE IN A
RADIATION THERAPY MACHINE (OLIVERA Gustavo H, KAPATOES Jeffrey M, MACKIE Thomas R, RECKWERDT Paul
J, FITCHARD Edward E, ZACHMAN Julie C)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P99026US
	 	UNITED STATES	 	 	6560311	 	 	 	5/6/03	 	 	 	09/762282	 
	P99026WO
	 	W.I.P.O.	 	 	 	 	 	 	 	 	 	US99/17674	 
	P99026EP
	 	EPO	 	 	1102610	 	 	 	 	 	 	 	99940881.8	 
	P99026AU
	 	AUSTRALIA	 	 	757570	 	 	 	6/19/03	 	 	 	54653/99	 
	P99026CA
	 	CANADA	 	 	2339534	 	 	 	2/17/04	 	 	 	2339534	 
	P99026FR
	 	FRANCE	 	 	 	 	 	 	 	 	 	 	99940881.8	 
	P99026DE
	 	GERMANY	 	 	69934893	 	 	 	11/8/07	 	 	 	99940881.8	 
	P99026GB
	 	GREAT BRITAIN	 	 	 	 	 	 	 	 	 	 	99940881.8	 
	P99026IL
	 	ISRAEL	 	 	141292	 	 	 	3/19/06	 	 	 	141292	 
	P99026JP
	 	JAPAN	 	 	3775993	 	 	 	3/3/06	 	 	 	2000-563349	 
	P99026KR
	 	KOREA	 	 	 	 	 	 	 	 	 	 	2001-7001599	 
	P99026MX
	 	MEXICO	 	 	222855	 	 	 	9/22/04	 	 	 	2001-001370	 
	P99026NL
	 	NETHERLANDS	 	 	 	 	 	 	 	 	 	 	99940881.8	 
	P99026NZ
	 	NEW ZEALAND	 	 	509668	 	 	 	6/8/04	 	 	 	509668	 

 

 

 

METHOD AND APPARATUS FOR CALIBRATION OF RADIATION THERAPY EQUIPMENT AND VERIFICATION OF
RADIATION TREATMENT (MACKIE Thomas R, RECKWERDT Paul J, MCNUTT Todd R)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P02190US
	 	UNITED STATES	 	 	6636622	 	 	 	10/21/03	 	 	 	10/038379	 

MEGAVOLTAGE COMPUTED TOMOGRAPHY DURING RADIOTHERAPY (MACKIE Thomas R, RUCHALA Kenneth J,
OLIVERA Gustavo H)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P99192US
	 	UNITED STATES	 	 	6618467	 	 	 	9/9/03	 	 	 	09/913084	 
	P99192CA
	 	CANADA	 	 	2368764	 	 	 	3/2/05	 	 	 	2368764	 
	P99192DE
	 	GERMANY	 	 	60018394.7	 	 	 	3/2/05	 	 	 	00921493.3	 
	P99192EP
	 	EPO	 	 	1165182	 	 	 	3/2/05	 	 	 	00921493.3	 
	P99192FR
	 	FRANCE	 	 	1165182	 	 	 	3/2/05	 	 	 	00921493.3	 
	P99192GB
	 	GREAT BRITAIN	 	 	1165182	 	 	 	3/2/05	 	 	 	00921493.3	 
	P99192IL
	 	ISRAEL	 	 	145292	 	 	 	1/6/07	 	 	 	145292	 
	P99192JP
	 	JAPAN	 	 	3746679	 	 	 	12/2/05	 	 	 	2000-609134	 
	P99192NL
	 	NETHERLANDS	 	 	1165182	 	 	 	3/2/05	 	 	 	00921493.3	 
	P99192PV
	 	PROVISIONAL	 	 	 	 	 	 	 	 	 	 	60/127630	 
	P99192SE
	 	SWEDEN	 	 	1165182	 	 	 	3/2/05	 	 	 	00921493.3	 
	P99192WO
	 	W.I.P.O	 	 	 	 	 	 	 	 	 	US00/08291	 

 

 

 

RADIATION DETECTOR WITH LATERALLY ACTING CONVERTERS (HINDERER Ralf, KELLER Harald, MACKIE
Thomas R, KAPATOES Jeffrey M, PEARSON David W, RECKWERDT Paul J, SCHMIDT Richard C)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P01199US
	 	UNITED STATES	 	 	7186986	 	 	 	3/6/07	 	 	 	10/451932	 
	P01199CA
	 	CANADA	 	 	 	 	 	 	 	 	 	 	2450229	 
	P01199EP
	 	EPO	 	 	 	 	 	 	 	 	 	 	02742149.4	 
	P01199PV
	 	PROVISIONAL	 	 	 	 	 	 	 	 	 	 	60/299097	 
	P01199WO
	 	W.I.P.O.	 	 	 	 	 	 	 	 	 	US02/19154	 

[ * ]

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P02341US
	 	UNITED STATES	 	 	 	 	 	 	 	 	 	 	10/715986	 
	P02341EP
	 	EPO	 	 	 	 	 	 	 	 	 	 	04755204.7	 
	P02341WO
	 	W.I.P.O.	 	 	 	 	 	 	 	 	 	US2004/018890	 
	P02341DE
	 	GERMANY	 	 	 	 	 	 	 	 	 	 	04755204.7	 
	P02341FR
	 	FRANCE	 	 	 	 	 	 	 	 	 	 	04755204.7	 
	P02341GB
	 	GREAT BRITAIN	 	 	 	 	 	 	 	 	 	 	04755204.7	 
	P02341NL
	 	NETHERLANDS	 	 	 	 	 	 	 	 	 	 	04755204.7	 
	P02341SE
	 	SWEDEN	 	 	 	 	 	 	 	 	 	 	04755204.7	 

[ * ]

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P03220US
	 	UNITED STATES	 	 	 	 	 	 	 	 	 	 	10/702810	 
	P03220EP
	 	EPO	 	 	 	 	 	 	 	 	 	 	04755202.1	 
	P03220PV
	 	PROVISIONAL	 	 	 	 	 	 	 	 	 	 	60/478584	 
	P03220WO
	 	W.I.P.O.	 	 	 	 	 	 	 	 	 	US2004/018888	 

 

 

 

CORRECTION OF PATIENT ROTATION ERRORS IN RADIOTHERAPY USING COUCH TRANSLATION (MACKIE Thomas R,
BOSWELL Sarah A, JERAJ Robert , KELLER Harald, KISSICK Michael W, *PEARSON David W, *OLIVERA
Gustavo H, *RUCHALA Kenneth J)

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P03382US
	 	UNITED STATES	 	 	7302038	 	 	 	11/27/07	 	 	 	10/949831	 

[ * ]

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P04215US
	 	UNITED STATES	 	 	 	 	 	 	 	 	 	 	11/110461	 
	P04215PV
	 	PROVISIONAL	 	 	 	 	 	 	 	 	 	 	60/618846	 

[ * ]

	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	P07283US
	 	UNITED STATES	 	 	 	 	 	 	 	 	 	 	 	 
	P07283WO
	 	W.I.P.O.	 	 	 	 	 	 	 	 	 	PCT/US08/55161

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}]]